Gunderson Dettmer advised Arcus Biosciences on the deal Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the pricing…
Arcus Biosciences’ $138 Million Initial Public Offering
